Fluwastatyna sodowa CAS:93957-55-2

Fluvastatin is an inhibitor of HMG-CoA reductase that is clinically used to lower cholesterol and treat cardiovascular disease. Fluvastatin exhibits anti-hyperlipidemic, anti-fibrotic, cardioprotective, antiviral, antithrombotic, antioxidative, vasorelaxant, anti-atherosclerotic, and anticancer activities. Fluvastatin suppresses viral load of hepatitis C virus in a clinical setting and prevents viral replication. In vitro, fluvastatin decreases platelet activation by increasing PECAM-1 signaling and inhibiting activation of Akt. Dodatkowo, fluvastatin scavenges hydroxyl radicals in vitro. In other cellular models, fluvastatin increases expression of NO and phospholipase 2 (PLA2) and decreases levels of angiotensin II (AT II) and ROCK. Dodatkowo, this compound induces apoptosis and G2/M phase cell cycle arrest, decreases the mitochondrial membrane potential, and increases release of cytochrome c and activation of caspase 3 in hepatocellular carcinoma cells. In animal models of cardiac distress, fluvastatin improves left ventricular function and prevent fibrosis by inhibiting RhoA and decreasing levels of CTFG and fibronectin.

Fluvastatin sodium salt is commonly used as a cholesterol-lowering drug, cholesterol-lowering effect is very good, the trade name of the commercially available products is Lescol,which is produced by Novartis. Fluvastatin sodium salt is a fully synthetic cholesterol-lowering drug, it belongs to methylglutaryl coenzyme A (HMC-CoA) reductase inhibitors, the main function is performed in the liver ,it can transform HMG-CoA into 3-methyl - 3,5-dihydroxy acid, it can inhibit the synthesis of endogenous cholesterol ,and reduce cholesterol content in liver cells, it can stimulate the synthesis of low density lipoprotein (LDL) receptors,and enhance the uptake of LDL particles, reduce the plasma total cholesterol concentration.it can significantly reduce total cholesterol, LDL cholesterol, triglycerides, and increase high-density lipoprotein cholesterol.